Guillaume Mabilleau

Depth and volume of resorption induced by osteoclasts generated in the presence of RANKL, TNF-alpha/IL-1 or LIGHT.

Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties.

Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?

Glucose-dependent insulinotropic polypeptide (GIP) directly affects collagen fibril diameter and collagen cross-linking in osteoblast cultures.

Alteration of the bone tissue material properties in type 1 diabetes mellitus: A Fourier transform infrared microspectroscopy study.

Incretins and bone: friend or foe?

A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus.

High fat-fed diabetic mice present with profound alterations of the osteocyte network.

Interplay between bone and incretin hormones: A review.

Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption.

Incretin-based therapy for the treatment of bone fragility in diabetes mellitus.

Sitagliptin Alters Bone Composition in High-Fat-Fed Mice.

Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.

GIP analogues augment bone strength by modulating bone composition in diet-induced obesity in mice.

Dapagliflozin and Liraglutide Therapies Rapidly Enhanced Bone Material Properties and Matrix Biomechanics at Bone Formation Site in a Type 2 Diabetic Mouse Model.

Predicting Bone Regeneration with a Simple Blood Test.

Osteomorphs as a tool for personalized medicine.

Validation of Fourier Transform Infrared Microspectroscopy for the Evaluation of Enzymatic Cross-Linking of Bone Collagen.

Gut hormone analogues and skeletal health in diabetes and obesity: Evidence from preclinical models.

Gut hormones and bone homeostasis: potential therapeutic implications.